日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis

按体重指数校正的甲氨蝶呤剂量评估托法替尼和阿达木单抗治疗类风湿性关节炎的疗效和安全性：一项事后分析

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-025-00823-0
Takeuchi, Tsutomu; Tanaka, Yoshiya; Yamanaka, Hisashi; Yamaoka, Kunihiro; Sugiyama, Naonobu; Iikuni, Noriko; Toyoizumi, Shigeyuki; Kwok, Kenneth; Tsai, Wen-Chan; Mysler, Eduardo; Moots, Robert J; Smolen, Josef S; Fleischmann, Roy
关节炎
发表日期：2026
文献求助 收藏

Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

在患有类风湿性关节炎且心血管疾病风险较高或较低的患者中，比较upadacitinib与adalimumab的获益风险分析

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2024-005371
Burmester, Gerd R; Mysler, Eduardo; Taylor, Peter; Hall, Stephen; Wick-Urban, Bettina; Garrison, Andrew; Gao, Tianming; Fish, Irina; Strengholt, Sander; Fleischmann, Roy
心血管
关节炎
心血管疾病
发表日期：2025
文献求助 收藏

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

抗 GM-CSF 奥替利单抗治疗类风湿性关节炎患者的长期安全性和有效性：三项 3 期随机试验的长期扩展研究 (contRAst X)

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2024-088869
Weinblatt, Michael E; Taylor, Peter C; McInnes, Iain B; Atsumi, Tatsuya; Strand, Vibeke; Takeuchi, Tsutomu; Bracher, Marguerite; Brooks, David; Curtis, Paula; Gupta, Anubha; Nijhawan, Rina; O'Shea, Ciara; Rayner, Kirsty; Saurigny, Didier; Shelton, Celia; Wang, Millie; Wang, Reena; Fleischmann, Roy M
关节炎
GM-CSF
M-CSF
发表日期：2025
文献求助 收藏

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

奥洛珠单抗联合甲氨蝶呤：106周治疗的安全性和有效性

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard-2023-225473
Feist, Eugen; Fleischmann, Roy M; Fatenejad, Saeed; Bukhanova, Daria; Grishin, Sergey; Kuzkina, Sofia; Luggen, Michael; Nasonov, Evgeniy; Samsonov, Mikhail; Smolen, Josef S
发表日期：2024
文献求助 收藏

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study

乌帕替尼与阿达木单抗治疗类风湿性关节炎患者的长期安全性和有效性：来自 3 期随机 SELECT-COMPARE 研究的 5 年数据

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2023-004007
Fleischmann, Roy; Swierkot, Jerzy; Penn, Sara K; Durez, Patrick; Bessette, Louis; Bu, Xianwei; Khan, Nasser; Li, Yihan; Peterfy, Charles G; Tanaka, Yoshiya; Mysler, Eduardo
SELE
OMP
COMP
OMPA
关节炎
发表日期：2024
文献求助 收藏

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND

SELECT-BEYOND 研究显示，对于生物制剂治疗无效的活动性类风湿关节炎患者，upadacitinib 的长期疗效可持续性：长达 5 年的结果

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2023-004037
van Vollenhoven, Ronald F; Hall, Stephen; Wells, Alvin F; Meerwein, Sebastian; Song, Yanna; Tanjinatus, Oishi; Fleischmann, Roy
关节炎
SELE
发表日期：2024
文献求助 收藏

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

SELECT-BEYOND 研究 5 年随访结果显示，对于生物制剂治疗反应不足或不耐受的类风湿性关节炎患者，upadacitinib 的疗效和安全性

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2023-003918
Fleischmann, Roy; Meerwein, Sebastian; Charles-Schoeman, Christina; Combe, Bernard; Hall, Stephen; Khan, Nasser; Carter, Kyle M; Camp, Heidi S; Rubbert-Roth, Andrea
关节炎
SELE
发表日期：2024
文献求助 收藏

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

SELECT-COMPARE 研究：类风湿性关节炎患者从 Upadacitinib 转换为 Adalimumab 治疗后的长期疗效和安全性：5 年数据

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-024-00658-1
Fleischmann, Roy; Blanco, Ricardo; Van den Bosch, Filip; Bessette, Louis; Song, Yanna; Penn, Sara K; McDearmon-Blondell, Erin; Khan, Nasser; Chan, Kelly; Mysler, Eduardo
SELE
OMP
COMP
OMPA
关节炎
发表日期：2024
文献求助 收藏

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

乌帕替尼在有心血管疾病风险的患者中的安全性概况：SELECT III期类风湿性关节炎临床项目的综合事后分析

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard-2023-223916
Fleischmann, Roy; Curtis, Jeffrey R; Charles-Schoeman, Christina; Mysler, Eduardo; Yamaoka, Kunihiro; Richez, Christophe; Palac, Hannah; Dilley, Deanne; Liu, Jianzhong; Strengholt, Sander; Burmester, Gerd
心血管
关节炎
SELE
心血管疾病
发表日期：2023
文献求助 收藏

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

抗 GM-CSF 奥替利单抗与沙利鲁单抗或安慰剂治疗对靶向治疗反应不足的类风湿性关节炎患者：一项 III 期随机试验 (contTRAst 3)

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard-2023-224449
Taylor, Peter C; Weinblatt, Michael E; McInnes, Iain B; Atsumi, Tatsuya; Strand, Vibeke; Takeuchi, Tsutomu; Bracher, Marguerite; Brooks, David; Davies, John; Goode, Christopher; Gupta, Anubha; Mukherjee, Sumanta; O'Shea, Ciara; Saurigny, Didier; Schifano, Lorrie A; Shelton, Celia; Smith, Julia E; Wang, Millie; Wang, Reena; Watts, Sarah; Fleischmann, Roy M
关节炎
GM-CSF
M-CSF
发表日期：2023
文献求助 收藏